89bio Presents Key Findings from ENLIVEN Phase 2b Trial
89bio, Inc. (NASDAQ: ETNB), a biopharmaceutical company committed to developing innovative treatments for liver and cardiometabolic diseases, has exciting news. The company will present new analyses from its Phase 2b ENLIVEN trial, which assesses the efficacy of pegozafermin in patients suffering from metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, during the esteemed AASLD The Liver Meeting® 2024.
Poster Presentation Highlights
At the upcoming meeting scheduled for November, four poster presentations will spotlight significant findings from the ENLIVEN trial.
Key Abstracts and Presenting Authors
The abstracts include:
- Biomarker response in MASH patients with high-risk baseline FAST scores: Findings by Naim Alkhouri, MD, will be revealed on November 15 from 8:00 AM to 5:00 PM PST.
- Pegozafermin's impact on cirrhosis progression: A post-hoc analysis presented by Jörn M. Schattenberg, MD, on November 15 from 8:00 AM to 5:00 PM PST.
- Machine Learning Insights: An analysis by Oliver Mansbach, BA/BS, scheduled for November 16 from 8:00 AM to 5:00 PM PST.
- Diagnostic potential of FAST and AGILE3+ scores: Presented again by Naim Alkhouri, MD, on November 16 from 8:00 AM to 5:00 PM PST.
Understanding MASH and Its Treatment
Metabolic dysfunction-associated steatohepatitis (MASH), a serious form of liver disease, is characterized by liver fat accumulation, inflammation, and potential fibrosis. With rising numbers projected to affect millions, it is crucial to target treatments aimed at improving liver health and reducing complications such as cirrhosis and cardiovascular implications.
Treating advanced fibrosis requires a multidisciplinary approach, emphasizing the importance of timely intervention to prevent complications. MASH's complex nature necessitates effective therapeutic strategies to significantly enhance patient outcomes.
Insights into the ENLIVEN Trial
The ENLIVEN trial, a pivotal Phase 2b study, was meticulously designed to evaluate the safety and efficacy of weekly or biweekly pegozafermin dosing. Involving 192 participants, the study's primary goals focused on resolution rates of MASH and improvements in fibrosis staging after 24 weeks.
Results demonstrated remarkable efficacy, achieving high statistical significance—particularly with the 30 mg QW and 44 mg Q2W dosing regimens. These findings significantly contribute to understanding pegozafermin's therapeutic potential, with published results available for further exploration.
The Mechanism of Pegozafermin
Pegozafermin, an engineered glycoPEGylated analog of fibroblast growth factor 21, aims to combat MASH and related hypertriglyceridemia. Clinical trials have highlighted its ability to not only reduce triglyceride levels but also improve insulin sensitivity and liver inflammation, showcasing its broad therapeutic profile.
About 89bio and Future Directions
Headquartered in San Francisco, 89bio is dedicated to creating and advancing best-in-class solutions for individuals struggling with liver and metabolic diseases. With an active focus on moving pegozafermin swiftly through clinical trials, the company exemplifies commitment in an area desperately needing innovation.
The firm is pursuing exciting developments not only in MASH but also in related indications through ongoing Phase 3 trials, positioning itself favorably within the biopharmaceutical landscape.
Frequently Asked Questions
What is the ENLIVEN trial?
The ENLIVEN trial is a Phase 2b study evaluating the safety and effectiveness of pegozafermin in treating patients with metabolic dysfunction-associated steatohepatitis (MASH).
What are the key findings from the recent posters at AASLD?
The posters showcase various analyses, including biomarker responses, potential impacts on fibrosis progression, and the use of machine learning in treatment assessments.
What is the significance of pegozafermin?
Pegozafermin is designed to address the complex issues of MASH and severe hypertriglyceridemia, demonstrating promising results in improving liver function and metabolic parameters.
How does MASH affect patients?
MASH can lead to serious liver complications, including cirrhosis and hepatocellular carcinoma, greatly affecting patients' overall health and survival.
Where can I find more information about 89bio?
For detailed insights, you may contact 89bio directly or visit their official website.
